On July 17, Dr. Yaoyu Chen, Co-founder of Allorion Therapeutics (Allorion), and Dr. Jiaqi Liang, Head of Biology, visited Medicilon's Chuansha campus in Shanghai to present the "Excellent Service Award" to Medicilon's pharmacology department. They also engaged in discussions with Dr. Baohong Cao, Vice President of Medicilon Pharmacology Department, Dr. Wei Sun, Director of Pharmacology Department, and the core SD team about further deepening the collaboration between the two parties.
The presentation of the "Excellent Service Award" is not only a recognition of Medicilon's innovative capabilities and service quality by Allorion, but also a promising indication of deeper collaboration in the future.
At the symposium, Dr. Yaoyu Chen gained a comprehensive understanding of Medicilon's one-stop preclinical service platform in various cutting-edge fields such as antibodies, peptides, ADCs, PROTACs, mRNA vaccines, oligonucleotide drugs, and cell and gene therapy (CGT). Dr. Chen expressed admiration for Medicilon's strong research and development capabilities and innovative prowess in advancing biopharmaceutical innovation. The teams from both sides engaged in in-depth discussions on the latest progress of current collaborative projects, the achievement of key milestones, and future collaboration directions. They also jointly envisioned the vast prospects and limitless possibilities of the biopharmaceutical industry.
Both parties expressed their intention to use this award as an opportunity to further strengthen their collaborative foundation, expand areas of collaboration, deepen the essence of their collaboration, and jointly promote the vigorous development of biopharmaceutical innovation.
Allorion Therapeutics focuses on developing novel small molecule drugs for the treatment of cancer and autoimmune diseases. Committed to creating drugs with unique mechanisms of action, Allorion has successfully completed overseas licensing for two innovative drugs, showcasing its strong research and development capabilities and global vision. Meanwhile, Medicilon, as a one-stop preclinical research service platform for biopharmaceuticals, boasts over 410 tumor efficacy models and more than 230 non-tumor target research animal models. Additionally, Medicilon has extensive pharmacological evaluation methods for small molecule drugs and biologics, including monoclonal antibodies, bispecific antibodies, ADCs, PD-1/PD-L1 immune checkpoint inhibitors, oncolytic viruses, and CAR-T cell therapies. This robust capability provides strong support for new drug development. The complementary strengths of both parties have laid a solid and robust foundation for their collaboration.
Dr. Yaoyu Chen, co-Founder of Allorion Therapeutics, stated, "Medicilon's high-quality and efficient preclinical research services have provided solid support for the rapid advancement of our projects and given us a competitive edge in the global market. Looking ahead, we are filled with anticipation and hope that through close collaboration and complementary strengths, we can jointly explore the limitless potential of new drug development and meet the clinical needs of patients as soon as possible."
Dr. Baohong Cao, Vice President of Medicilon Pharmacology Department, stated, "We are honored and encouraged to receive recognition and trust from Allorion Therapeutics. This accolade not only affirms our past efforts but also serves as a motivation for future collaboration. We will take this opportunity to continue upholding our commitment to technological innovation, continually push the boundaries of research and development technologies, and upgrade our research service platform to empower more innovative drug development with even more efficient and high-quality services."
Allorion Therapeutics is a biopharmaceutical company focused on developing novel small molecule drugs for the treatment of cancer and autoimmune diseases. The company boasts a highly experienced team specializing in drug discovery and development, dedicated to creating novel small molecule drugs with unique mechanisms of action. By establishing innovative informatics and screening platforms, the company continuously advances the development of new drugs with high clinical value. Allorion Therapeutics is dedicated to providing patients with more effective and safer treatment options.
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of April 2024, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 480 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.
Relevant
news
marketing@medicilon.com
